Drug Patents owned by Glaxosmithkline

1. Drug name - ADVIL ALLERGY SINUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines Feb, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
2MG;200MG;30MG TABLET;ORAL Over the counter

2. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

CN1976701A GLAXOSMITHKLINE Machrs Antagonist
May, 2012

(10 years ago)

CN101701006B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN101701006A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN1585633B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN1585633A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN103288793A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN103288793B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

IN212714B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(23 days ago)

IN200400346P2 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(23 days ago)

IN255064B GLAXOSMITHKLINE 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2042168B1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

EP2042168A1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

EP2570128A1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1425001A1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

EP1425001B1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

3. Drug name - ARNUITY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser Feb, 2029

(6 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.05MG/INH POWDER;INHALATION Prescription
0.1MG/INH POWDER;INHALATION Prescription
0.2MG/INH POWDER;INHALATION Prescription

4. Drug name - CHILDREN'S ADVIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition May, 2024

(1 year, 7 months from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/5ML SUSPENSION;ORAL Over the counter

5. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
1MG/5ML;100MG/5ML;15MG/5ML SUSPENSION;ORAL Over the counter

6. Drug name - NICORETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323683 GLAXOSMITHKLINE Flavoring of drug-containing chewing gums Apr, 2028

(5 years from now)

US8940772 GLAXOSMITHKLINE Nicotine lozenge composition Apr, 2029

(6 years from now)

US8501164 GLAXOSMITHKLINE Nicotine lozenge compositions Jun, 2029

(6 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Treatment: NA

Dosage: GUM, CHEWING;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE GUM, CHEWING;BUCCAL Over the counter

7. Drug name - TRELEGY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

CN1976701A GLAXOSMITHKLINE Machrs Antagonist
May, 2012

(10 years ago)

CN101701006B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN101701006A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN1585633B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN1585633A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN103288793A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

CN103288793B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

IN212714B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(23 days ago)

IN200400346P2 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(23 days ago)

IN255064B GLAXOSMITHKLINE 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2042168B1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

EP2042168A1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(23 days ago)

EP2570128A1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1425001A1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

EP1425001B1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

8. Drug name - VENTOLIN HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXOSMITHKLINE Actuation indicator for a dispensing device Jun, 2023

(8 months from now)

US7832351

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device Dec, 2023

(1 year, 2 months from now)

US7500444 GLAXOSMITHKLINE Actuation indicator for a dispensing device Feb, 2026

(3 years from now)

US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device Aug, 2026

(3 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.09MG BASE/INH AEROSOL, METERED;INHALATION Prescription

9. Drug name - ZEJULA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436185 GLAXOSMITHKLINE Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(6 years from now)

US8071623 GLAXOSMITHKLINE Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(8 years from now)

CN101932572A GLAXOSMITHKLINE Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3-Yl]Phenyl}-2H-Indazole-7-Carboxamide
Nov, 2016

(5 years ago)

CN101415686A GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Apr, 2027

(4 years from now)

CN101415686B GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose) Polymerase (Parp) Inhibitor
Apr, 2027

(4 years from now)

CN101578279B GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

CN101578279A GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose) Polymerase(Parp) Inhibitors
Jan, 2028

(5 years from now)

IN288260B GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adpribose) Polymerase (Parp) Inhibitors
Apr, 2027

(4 years from now)

IN200808150P1 GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose)Polymerase (Parp) Inhibitors
Apr, 2027

(4 years from now)

EP2007733B1 GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Apr, 2027

(4 years from now)

EP2007733A1 GLAXOSMITHKLINE Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Apr, 2027

(4 years from now)

EP2336120B1 GLAXOSMITHKLINE Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2805945A1 GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2336120A1 GLAXOSMITHKLINE Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2805945B1 GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2109608A1 GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2109608B1 GLAXOSMITHKLINE Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors
Jan, 2028

(5 years from now)

EP2240466B1 GLAXOSMITHKLINE Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide
Jan, 2029

(6 years from now)

EP2240466A1 GLAXOSMITHKLINE Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide
Jan, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 GLAXOSMITHKLINE DNA damage repair inhibitors for the treatment of cancer Aug, 2027

(4 years from now)

US8143241 GLAXOSMITHKLINE DNA damage repair inhibitors for treatment of cancer Aug, 2027

(4 years from now)

US8859562 GLAXOSMITHKLINE Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Aug, 2031

(8 years from now)

US11091459 GLAXOSMITHKLINE Niraparib compositions Mar, 2038

(15 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.